Live Breaking News & Updates on Zydus

Stay updated with breaking news from Zydus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bayer Zydus Pharma: Bayer acquires remaining 25% stake in Bayer Zydus Pharma Pvt Ltd to secure full ownership

Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited have concluded their joint venture, Bayer Zydus Pharma Private Limited (BZPPL), established in 2011 for pharmaceutical sales and marketing in India. Bayer is now acquiring full ownership of the entity as per pre-agreed terms. The joint venture successfully combined Zydus s Indian marketing expertise and distribution network with Bayer s global innovation, making strides in various therapeutic areas. ....

Shweta Rai , Zydus Lifesciences , Bayer Pharmaceuticals Private , Health For , Country Division Head , Bayer Pharmaceuticals , Bayer Zydus Pharma Private Limited , Bayer Pharmaceuticals Private Limited , Zydus Lifesciences Limited , Cadila Healthcare , Zydus Pharma Private Limited , Managing Director , Bayer Zydus Pharma , Bayer Zydus Pharma Pvt , Bayer News , Bayer Pharma , Health Solutions , Pharmaceutical Products ,

cdmo: Foram Parekh on what to bet on in pharma pack

Foram Parekh shares insights on CDMO companies positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus s earnings improvement, Sun Pharma s specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy s. ....

Dadra And Nagar Haveli , Uttar Pradesh , Sun Pharma , Foram Parekh , Offering College , Indian School Of Business , Associatev P , Leadership Excellence , Executive Officer , Operations Officer , Biosecure Law , Might Also Like , Pithampur Unit , Us Fda , Sharekhan By Bnp Paribas , Expert View , Stock Market , Et Now ,

Zydus Wellness stocks: Buy Zydus Wellness, target price Rs 1910: Anand Rathi

Zydus Wellness Ltd. key Products/Revenue Segments include Personal Care and Other Operating Revenue for the year ending 31-Mar-2023. ....

Economic Times , Zydus Wellness Stocks , Market News , Zydus Wellness , Zydus Ltd , Zydus Wellness Ltd , Zydus Wellness Ltd ,

Zydus aims to launch first new drug in US by early 2026

Zydus will enter a competitive field, with an FDA decision on CymaBay s PBC drug due in August. Gilead Sciences announced its acquisition of CymaBay for $4.3 billion earlier in February. Saroglitazar, currently in a mid-to-late-stage trial for PBC, is also being tested for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a type of fatty liver disease." ....

United States , Zydus Lifesciences , Sun Pharma Cipla , Sharvil Patel , Novo Nordisk , Gilead Sciences , Managing Director Sharvil Patel , Primary Biliary Cholangitis , Metabolic Dysfunction Associated Steatohepatitis , Liver Disease , Early 2026 , New Drug , Sun Pharma ,